Literature DB >> 16047163

Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma.

Susannah Cleary1, Frederieke M Brouwers, Graeme Eisenhofer, Karel Pacak, David L Christie, Janusz Lipski, Alan R McNeil, Jacqueline K Phillips.   

Abstract

Expression of the noradrenaline transporter (NAT) was examined in normal human adrenal medulla and phaeochromocytoma by using immunohistochemistry and confocal microscopy. The enzymes tyrosine hydroxylase (TH) and phenylethanolamine N-methyltransferase (PNMT) were used as catecholamine biosynthetic markers and chromogranin A (CGA) as a marker for secretory granules. Catecholamine content was measured by using high performance liquid chromatography (HPLC). In normal human adrenal medulla (n=5), all chromaffin cells demonstrated strong TH, PNMT and NAT immunoreactivity. NAT was co-localized with PNMT and was located within the cytoplasm with a punctate appearance. Human phaeochromocytomas demonstrated strong TH expression (n=20 samples tested) but variable NAT and PNMT expression (n=24). NAT immunoreactivity ranged from absent (n=3) to weak (n=10) and strong (n=11) and, in some cases, occupied an apparent nuclear location. Unlike the expression seen in normal human adrenal medullary tissue, NAT expression was not consistently co-localized with PNMT. PNMT also showed highly variable expression that was poorly correlated with tumour adrenaline content. Immunoreactivity for CGA was colocalized with NAT within the cytoplasm of normal human chromaffin cells (n=4). This co-localization was not consistent in phaeochromocytoma tumour cells (n=7). The altered pattern of expression for both NAT and PNMT in phaeochromocytoma indicates a significant disruption in the regulation and possibly in the function of these proteins in adrenal medullary tumours.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047163     DOI: 10.1007/s00441-005-0026-y

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  8 in total

1.  Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma.

Authors:  Lucia Martiniova; Susannah Cleary; Edwin W Lai; Dale O Kiesewetter; Jurgen Seidel; Linda F Dawson; Jacqueline K Phillips; David Thomasson; Xiaoyuan Chen; Graeme Eisenhofer; James F Powers; Richard Kvetnansky; Karel Pacak
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

2.  Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.

Authors:  Graeme Eisenhofer; Karel Pacak; Thanh-Truc Huynh; Nan Qin; Gennady Bratslavsky; W Marston Linehan; Massimo Mannelli; Peter Friberg; Stefan K Grebe; Henri J Timmers; Stefan R Bornstein; Jacques W M Lenders
Journal:  Endocr Relat Cancer       Date:  2010-12-21       Impact factor: 5.678

3.  Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.

Authors:  Thanh-Truc Huynh; Karel Pacak; Frederieke M Brouwers; Mones S Abu-Asab; Robert A Worrell; Macclellan M Walther; Abdel G Elkahloun; David S Goldstein; Susannah Cleary; Graeme Eisenhofer
Journal:  Eur J Endocrinol       Date:  2005-10       Impact factor: 6.664

Review 4.  Metastatic paraganglioma.

Authors:  Stephanie M J Fliedner; Hendrik Lehnert; Karel Pacak
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

5.  MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice.

Authors:  Shoichiro Ohta; Edwin W Lai; John C Morris; Douglas A Bakan; Brenda Klaunberg; Susannah Cleary; James F Powers; Arthur S Tischler; Mones Abu-Asab; Daniel Schimel; Karel Pacak
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

6.  Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.

Authors:  Susannah Cleary; Jacqueline K Phillips; Thanh-Truc Huynh; Karel Pacak; Abdel G Elkahloun; Jennifer Barb; Robert A Worrell; David S Goldstein; Graeme Eisenhofer
Journal:  J Endocrinol       Date:  2007-05       Impact factor: 4.286

Review 7.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

8.  Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene.

Authors:  Henri J L M Timmers; Karel Pacak; Thanh T Huynh; Mones Abu-Asab; Maria Tsokos; Maria J Merino; Bora E Baysal; Karen T Adams; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-07       Impact factor: 5.958

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.